Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Pari Pharma has reported that its eFlow, an advanced electronic nebulizer, was optimized and used to deliver Alnylam's ALN-RSV01 in a Phase I human clinical trial.
Subscribe to our email newsletter
Alnylam’s Phase I study for ALN-RSV01 was a randomized, double-blind, placebo-controlled trial in healthy adult volunteers to assess the safety, tolerability, and pharmacokinetics of ALN-RSV01 administrated by inhalation via nebulizer. All major objectives of the trial were met, including definition of a safe and well-tolerated dose and regimen for advancement of ALN-RSV01 into further Phase II development. Importantly, data showed that the efficiency of delivery of ALN-RSV01 delivered via inhalation, as measured by plasma levels, was significantly greater in humans than observed pre-clinically.
ALN-RSV01 is an RNAi therapeutic being developed as a treatment for respiratory syncytial virus (RSV) infection, the leading cause of pediatric hospitalization in the US and a prevalent infection in immune-compromised adults. The Phase I study represents the first-ever clinical study of an RNAi therapeutic administered via inhalation.